369403-44-1

Basic information

• Product Name: 2-(4-Biphenylyl)-2-(Boc-aMino)acetic Acid
• Synonyms: 2-(4-Biphenylyl)-2-(Boc-aMino)acetic Acid;a-(Boc-aMino)-biphenyl-4-acetic acid
• CAS NO: 369403-44-1
• Molecular Formula: C₁₉H₂₁NO₄
• Molecular Weight: 327.37434
• Mol File: 369403-44-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(4-Biphenylyl)-2-(Boc-aMino)acetic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-Biphenylyl)-2-(Boc-aMino)acetic Acid(369403-44-1)
• EPA Substance Registry System: 2-(4-Biphenylyl)-2-(Boc-aMino)acetic Acid(369403-44-1)

Safety Data

• Hazardous Substances Data: 369403-44-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-Biphenylyl)-2-(Boc-aMino)acetic Acid is used as a building block for the production of diverse pharmaceutical compounds. Its stability and compatibility in chemical reactions make it suitable for the synthesis of biologically active compounds.
Used in Peptide Synthesis:
2-(4-Biphenylyl)-2-(Boc-aMino)acetic Acid is used as a key intermediate in the chemical synthesis of peptides. Its Boc-protected amino group allows for coupling reactions in peptide synthesis, facilitating the creation of complex peptide structures.
Used in Drug Development:
2-(4-Biphenylyl)-2-(Boc-aMino)acetic Acid has potential applications in the development of new drug molecules and materials with specific properties. Its unique structure and reactivity contribute to the discovery and design of innovative pharmaceutical agents.

Upstream product

• 119397-06-7 2-amino-2-(4-bromophenyl)acetic acid 
• 709665-73-6 methyl 2-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)acetate 
• 42718-15-0 methyl 2-amino-2-(4-bromophenyl)acetate 
• 917925-71-4 2-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)acetic acid 
• 98-80-6 phenylboronic acid 

Downstream Products

• 221101-61-7 2-([1,1’-biphenyl]-4-yl)glycine 

Relevant articles and documents

Synthesis method of 2-([1, 1 '-biphenyl]-4-yl)-2-glycine compound

The invention relates to a synthesis method of a 2-([1, 1 '-biphenyl]-4-yl)-2-glycine compound. The method comprises the following steps: performing suzuki reaction on a compound as shown in a formulaI and a compound as shown in a formula II in the presence of alkali, a solvent and a catalyst under inert gas protection and microwave-assisted conditions to prepare an intermediate compound, and then deprotecting the intermediate compound to prepare a compound as shown in a formula III, wherein the structural formula of the compound shown in the formula I is shown in the specification, the structural formula of the compound shown in the formula II is shown in the specification, the structural formula of the compound shown in the formula III is shown in the specification, and in the formula Iand the formula III, R is one of H, alkyl, alkoxy, halogen and trifluoromethyl. The synthesis method is low in toxicity, high in safety coefficient, easy and convenient to operate, easy to control and efficient in reaction, and the yield reaches up to 81% or above. In the synthesis method, microwave assistance is added for a certain time in the suzuki reaction process, so that the reaction is promoted, the reaction efficiency is effectively improved, and the reaction time is shortened.

Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions

Malaria remains a global health problem, and though international efforts for treatment and eradication have made some headway, the emergence of drug-resistant parasites threatens this progress. Antimalarial therapeutics acting via novel mechanisms are urgently required. Plasmodium falciparum M1 and M17 are neutral aminopeptidases which are essential for parasite growth and development. Previous work in our group has identified inhibitors capable of dual inhibition of PfA-M1 and PfA-M17, and revealed further regions within the protease S1 pockets that could be exploited in the development of ligands with improved inhibitory activity. Herein, we report the structure-based design and synthesis of novel hydroxamic acid analogues that are capable of potent inhibition of both PfA-M1 and PfA-M17. Furthermore, the developed compounds potently inhibit Pf growth in culture, including the multi-drug resistant strain Dd2. The ongoing development of dual PfA-M1/PfA-M17 inhibitors continues to be an attractive strategy for the design of novel antimalarial therapeutics.